{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 12/80', 'Minor edits and administrative updates throughout the protocol.', 'Applicable Sections:', 'Title Page', 'Section 2.2.1 Clinical Safety', 'Signature Page - Sponsor', 'Appendix 2', 'Amendment 1 (13-Nov-2018)', 'The overall reason for this amendment:', 'Subject exclusion criteria were revised to comply with the', 'Law and facilitate subject', 'recruitment.', 'The changes made to the CSP GLPG1690-CL-204 Version 2.00, {20-aug-2018}, are listed below,', 'reflecting a brief rationale of each change and the applicable sections.', 'Rationale: The protocol was updated to revise the definition of abnormal renal function in', 'exclusion criterion 19. The initial exclusion criterion was too stringent for this patient population.', \"The change is not expected to affect subjects' safety.\", 'Applicable Sections: 4.5.2 Exclusion Criteria', 'Rationale: The protocol was updated to add an exclusion criteria 30 to comply with the', 'Applicable Sections: 4.5.2 Exclusion Criteria', 'Rationale: The procedure for collection of informed consent of a patient unable to read and/or write', 'was amended to comply with the', 'Applicable Sections: 10.4.2 Informed Consent', 'Rationale: The protocol was updated to delete Appendix 1 with normal ranges for vital signs and', 'ECG parameters. The clinical significance of vital signs and ECG assessments is to be at the', \"investigator's discretion.\", 'Applicable Sections: Appendix 1', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 13/80', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', 'Abbreviations', 'ACR', 'American College of Rheumatology', 'AE', 'adverse event', 'ALAT', 'Latin American Thoracic Association', 'ALT', 'alanine aminotransferase', 'AST', 'aspartate aminotransferase', 'ATS', 'American Thoracic Society', 'ATX', 'autotaxin', 'BCRP', 'breast cancer resistance protein', 'b.i.d.', 'twice daily', 'BMI', 'body mass index', 'BW', 'body weight', 'cGvHD', 'chronic graft-versus-host disease', 'CI', 'confidence interval', 'CKD-EPI', 'Chronic Kidney Disease Epidemiology Collaboration', 'COVID-19', 'Coronavirus disease', 'CRF', 'case report form', 'CRO', 'contract research organization', 'CSP', 'clinical study protocol', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTFG', 'Clinical Trial Facilitation Group', 'CTGF', 'connective tissue growth factor', 'CYP', 'cytochrome P450', 'DBP', 'diastolic blood pressure', 'DTP', 'direct to patient', 'ECG', 'electrocardiogram', 'ED', 'early discontinuation', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 14/80', 'eGFR', 'estimated glomerular filtration rate', 'ENPP', 'ectonucleotide pyrophosphatase/phosphodiesterase', 'EoS', 'end of the study', 'ERS', 'European Respiratory Society', 'ET-1', 'endothelin-1', 'EU', 'European Union', 'EULAR', 'European League Against Rheumatism', 'FC', 'fold change', 'FSH', 'follicle stimulating hormone', 'FVC', 'forced vital capacity', 'GCP', 'Good Clinical Practice(s)', 'GGT', 'gamma glutamyl transferase', 'GLP', 'Good Laboratory Practice', 'HIV', 'human immunodeficiency virus', 'HMA', 'Heads of Medicines Agencies', 'IB', \"investigator's brochure\", 'IC50', '50% inhibitory concentration', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements', 'for Pharmaceuticals for Human Use', 'IEC', 'Independent Ethics Committee', 'IL-x', 'interleukin X', 'IMP', 'investigational medicinal product', 'INR', 'international normalized ratio', 'IPF', 'idiopathic pulmonary fibrosis', 'IRB', 'Institutional Review Board', 'IWRS', 'interactive web response system', 'JRS', 'Japanese Respiratory Society', 'LFT', 'liver function test', 'LPA', 'lysophosphatidic acid', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}